News articles about Viking Therapeutics (NASDAQ:VKTX) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Viking Therapeutics earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.6803741603247 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

A number of brokerages have commented on VKTX. Roth Capital set a $6.00 target price on Viking Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 29th. Maxim Group set a $8.00 target price on Viking Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 28th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Viking Therapeutics in a research report on Friday, November 10th. Finally, ValuEngine lowered Viking Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday.

Shares of Viking Therapeutics (VKTX) opened at $2.85 on Tuesday. Viking Therapeutics has a 52-week low of $0.88 and a 52-week high of $3.24.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). sell-side analysts forecast that Viking Therapeutics will post -0.86 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Insider Buying and Selling by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.